Concepedia

Author

Alessia Bottos

Roche (Switzerland)ORCID

Also Known As

A. Bottos, Alessia Bottos

160

Publications

906

Citations

16

H-Index

43

Concepts

All Affiliations

Roche (Switzerland)Roche (United Kingdom)RigshospitaletCandiolo Cancer InstituteUniversity Hospital of Basel
AB

About

Alessia Bottos is an author at Roche (Switzerland) specializing in medicine, vascular biology, and developmental biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

145

2

Health Sciences

2

2

26

3

Cell Biology

2

2

55

4

Natural Sciences

1

1

16

5

Social Sciences

1

1

64

Alessia Bottos

×

16

Publications

663

Citations

15

H-Index

YearCitations

Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways

Ymera Pignochino, Giovanni Grignani, Giuliana Cavalloni,

Molecular Cancer

2009

175

Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models

Alessia Bottos, Dagmar Gotthardt, Jason Gill,

Nature Communications

2016

100

The synaptic proteins neurexins and neuroligins are widely expressed in the vascular system and contribute to its functions

Alessia Bottos, Erika Destro, Alberto Rissone,

Proceedings of the National Academy of Sciences

2009

64

Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia

Alessia Bottos, Miriam Martini, Federica Di Nicolantonio,

Proceedings of the National Academy of Sciences

2011

58

Neuroligin 1 Induces Blood Vessel Maturation by Cooperating with the α6 Integrin

Anna Valeria Samarelli, E. Riccitelli, Laura Bizzozero,

Journal of Biological Chemistry

2014

39

Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Martin Hutchings, Anna Sureda, María José Terol,

Blood

2021

35

Transcriptional regulation of tenascin‐<scp>W</scp> by <scp>TGF</scp>‐beta signaling in the bone metastatic niche of breast cancer cells

Francesca Chiovaro, Enrico Martina, Alessia Bottos,

International Journal of Cancer

2015

32

Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study

Christiane Pott, Vindi Jurinović, Judith Trotman,

Journal of Clinical Oncology

2023

28

Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study

Michael Dickinson, Carmelo Carlo‐Stella, Franck Morschhauser,

Blood

2024

21

Patient‐reported outcomes provide prognostic information for survival in patients with diffuse large B‐cell lymphoma: Analysis of 1239 patients from the <scp>GOYA</scp> study

Huang Huang, Asim Datye, Ming Fan,

Cancer Medicine

2022

19

Page 1